TrialNCT06033586Phase 3Active not recruiting
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Study sponsor: Protagonist Therapeutics, Inc. · PTGX
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2026-04-01Estimated
Enrollment · participants46Actual
Source updated2025-08-06Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.